Biotech

All Articles

ArsenalBio raises $325M, pivots off of former lead asset

.Arsenal Biosciences is proceeding up. The cell therapy firm has added on $325 million in ammo along...

Lilly- backed fat burning biotech data IPO

.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has submitted...

Aelis' marijuana usage medication fails phase 2b, driving Indivior to reconsider $100M possibility

.Aelis Farma's hopes of protecting a simple, favorable decision on a $100 million possibility paymen...

ProKidney standstills period 3 trial certainly not needed to have for cell therapy confirmation

.ProKidney has actually ceased one of a pair of period 3 tests for its own cell therapy for renal il...

Vaxcyte rises on 'spectacular' 31-valent PCV gain versus Pfizer

.Vaxcyte revealed what experts called "stunning" period 1/2 data for its 31-valent pneumococcal vacc...

Recursion's brain condition test presents scant proof of efficacy

.Recursion has actually discovered with a very early examination of its own tech-enabled technique t...

Acepodia, Pfizer click all together for chemistry-based cell treatment

.Call it an instance of good chemistry: Acepodia, a biotech based on Nobel Champion scientific resea...

Praxis epilepsy medication lowers seizures in phase 2 trial

.Practice Preciseness Medicines has actually racked up an additional midphase win in epilepsy this y...

Three execs resign as Dyne blog posts mixed records for DMD prospect

.After running away a medical hold many years back, Dyne Therapy has actually uncovered brand new pe...

Arrowhead fires off stage 3 data in unusual metabolic illness in advance of market encounter Ionis

.Arrowhead Pharmaceuticals has actually presented its hand in front of a potential showdown with Ion...